Genoray

122310 · KOSDAQ · Health Care · SMALL CAP

Back to a net profit.

Genoray filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$23.6M (+18.4% year on year), operating profit of US$1.05M (from a loss a year earlier) and net income of US$2.1M (from a loss a year earlier).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-02-12· RCEPT 20260212900259

US$23.6MRevenue
+18.4%Revenue vs a year earlier
US$1.05MOperating profit

Converted at 1 USD ≈ ₩1,444.19 (filing-date rate, 2026-02-12 close)

What happened

Genoray filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$23.6M (+18.4% year on year), operating profit of US$1.05M (from a loss a year earlier) and net income of US$2.1M (from a loss a year earlier).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$23.6M
Revenue vs a year earlier+18.4%
Operating profitUS$1.05M
Net incomeUS$2.1M
PeriodQ4 2025 (consolidated)
Filed2026-02-12, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260212900259 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-02-12 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.